Asciminib for untreated Philadelphia-chromosome-positive chronic myeloid leukaemia in the chronic phase

  • Awaiting development
  • GID-TA12455
  • Expected publication date: TBC

Status:
Awaiting development
Technology type:
Medicine
Decision:
Selected
Prioritisation programme:
Medicines evaluation
Rationale:

Criteria within the VPAG met as a significant license extension. 

Process:
STA Standard

Timeline

Key events during the development of the guidance:

Date Update
10 June 2026 Awaiting development. Status change linked to topic prioritisation decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual